{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-026254","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.053703+00:00","generated_at":"2026-06-01T22:32:05.887396+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"STRATA Skin Sciences Q1 revenue $6.8M (-11% YoY); net loss widens to $3.4M","bullets":["Revenue $6.8M vs $7.6M YoY; global recurring revenue $4.7M (-10% YoY).","Net loss $3.4M ($0.10 per share) vs $2.8M ($0.08) in Q1 2023.","Gross margin fell to 46% from 58% YoY; operating expenses cut 14% to $6.0M.","Domestic installed base: 907 XTRAC (down from 923 in Dec 2023); 104 TheraClear X (up from 92).","Amended credit agreement with MidCap Financial; renewed 3-year exclusive distributor deals in China and Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-026254","json":"https://secwatch.observer/filing/0001140361-24-026254.json","markdown":"https://secwatch.observer/filing/0001140361-24-026254.md","text":"https://secwatch.observer/filing/0001140361-24-026254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124026254/0001140361-24-026254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124026254/ef20029015_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:32:05.887396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c74dbdf79d40e2ce8baefdf0b4b590815eccf999","claim":"STRATA Skin Sciences, Inc. reported the first fiscal quarter ended March 31, 2024 results: revenue $6.8 million, net income Net loss of $3.4 million, EPS net loss of $0.10 per basic and diluted common share.","evidence_excerpt":"announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 o Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124026254/0001140361-24-026254-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first fiscal quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.8 million"},{"label":"Net income","value":"Net loss of $3.4 million"},{"label":"EPS","value":"net loss of $0.10 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}